KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Raw Materials (2016 - 2025)

Sarepta Therapeutics (SRPT) has 10 years of Raw Materials data on record, last reported at $325.5 million in Q3 2025.

  • For Q3 2025, Raw Materials rose 56.27% year-over-year to $325.5 million; the TTM value through Sep 2025 reached $325.5 million, up 56.27%, while the annual FY2024 figure was $280.0 million, 109.05% up from the prior year.
  • Raw Materials reached $325.5 million in Q3 2025 per SRPT's latest filing, up from $314.9 million in the prior quarter.
  • Across five years, Raw Materials topped out at $325.5 million in Q3 2025 and bottomed at $40.2 million in Q3 2021.
  • Average Raw Materials over 5 years is $150.0 million, with a median of $134.0 million recorded in 2023.
  • Peak YoY movement for Raw Materials: surged 220.98% in 2021, then tumbled 74.29% in 2022.
  • A 5-year view of Raw Materials shows it stood at $230.2 million in 2021, then tumbled by 74.29% to $59.2 million in 2022, then surged by 126.36% to $134.0 million in 2023, then skyrocketed by 109.05% to $280.0 million in 2024, then grew by 16.25% to $325.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Raw Materials were $325.5 million in Q3 2025, $314.9 million in Q2 2025, and $299.0 million in Q1 2025.